IceCure Medical Ltd. Chief Executive Officer and Director Eyal Shamir filed a Form 4 on November 2, 2026, disclosing the acquisition of 404,901 restricted share units granted on August 11, 2026.
Key Highlights
- RSU Grant: Shamir acquired 404,901 restricted share units (RSUs) at a price of $0 on November 2, 2026, per the filing.
- Vesting Schedule: 25% of the RSUs vest on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25% each thereafter.
- Total Beneficial Ownership: Following the transaction, Shamir beneficially owned 431,281 securities, comprising 2,596 ordinary shares and 428,685 RSUs.
- Vested vs. Unvested RSUs: As of November 2, 2026, 9,862 RSUs had vested and 418,823 remained unvested, according to the filing.
- Reverse Share Split: The filing states that holdings were adjusted to reflect IceCure Medical's 1-for-30 reverse share split effected on June 4, 2026.
- Reporting Person Role: Shamir is identified in the filing as both a Director and Chief Executive Officer of IceCure Medical Ltd. (NASDAQ:ICCM).
IceCure Medical CEO Shamir's RSU Grant and Ownership Position
According to the Form 4 filed with the SEC on November 2, 2026, Eyal Shamir, Chief Executive Officer and Director of IceCure Medical Ltd. (NASDAQ:ICCM), reported the acquisition of 404,901 RSUs. The transaction code recorded is "A" (acquired), with a stated price of $0. The grant date of these RSUs was August 11, 2026, though the date of earliest transaction on the form is listed as November 2, 2026.
The filing describes the vesting terms for the RSUs: 25% vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% each following that date. Following this reported transaction, Shamir's total beneficial ownership stands at 431,281 securities, held directly. The filing breaks this figure down as 2,596 ordinary shares and 428,685 RSUs in aggregate, of which 9,862 RSUs have vested and 418,823 remain unvested as of November 2, 2026.
The filing notes that all holdings figures have been adjusted to reflect IceCure Medical's 1-for-30 reverse share split, which the company effected on June 4, 2026. The Form 4 was filed by one reporting person, and no derivative securities transactions were reported in Table II.
What Was Disclosed
Eyal Shamir, CEO and Director of IceCure Medical Ltd., disclosed the acquisition of 404,901 RSUs granted August 11, 2026, resulting in total beneficial ownership of 431,281 securities, as adjusted for the company's June 4, 2026 reverse share split.




Please wait processing your request...